EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of MCF-7 breast cancer cells with Tamoxifen and Faslodex augments complement resistance by increasing the expression of the complement regulators CD55 AND CD59



Treatment of MCF-7 breast cancer cells with Tamoxifen and Faslodex augments complement resistance by increasing the expression of the complement regulators CD55 AND CD59



International Immunopharmacology 2(9): 1269-1270, August




(PDF 0-2 workdays service: $29.90)

Accession: 035980527

Download citation: RISBibTeXText



Related references

High-level co-expression of complement regulators on vascular endothelium in transgenic mice: CD55 and CD59 provide greater protection from human complement-mediated injury than CD59 alone. Xenotransplantation 5(3): 184-190, 1998

Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. International Journal of Cancer 108(6): 930-936, 2004

The expression of the complement regulators CD46, CD55, and CD59 by human sperm does not protect them from antisperm antibody- and complement-mediated immune injury. Fertility and Sterility 59(4): 876-884, 1993

Expression and regulation of the membrane associated complement-regulators CD46, CD55 and CD59 in gastrointestinal cells. Gastroenterology 106(4 SUPPL ): A768, 1994

CD55 and CD59 expression protects HER2-overexpressing breast cancer cells from trastuzumab-induced complement-dependent cytotoxicity. Oncology Letters 14(3): 2961-2969, 2017

Expression of complement regulatory proteins CD55 and CD59 on breast cancer. Proceedings of the American Association for Cancer Research Annual Meeting 44: 363, July, 2003

Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59. European Journal of Immunology 35(7): 2175-2183, 2005

Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection. Plos One 8(9): E74880-E74880, 2014

Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial cells of patients on peritoneal dialysis therapy. Molecular Immunology 65(2): 302-309, 2015

Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. Journal Of Surgical Oncology. 64(3): 222-230, 1997

Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro. Current Cancer Drug Targets 10(8): 922-931, 2010

Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro. Current Cancer Drug Targets 10(8): 922-931, 2011

Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer. Journal of Gastrointestinal Surgery 5(6): 673-679, 2002

Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer. Journal of Gastrointestinal Surgery 5(6): 673-679, 2001

Expression and regulation of the membrane-associated complement regulators CD46, CD55 and CD59 in the pancreas. Digestion 55(5): 334-335, 1994